Correlation of AR, EGFR, and HER2 Expression Levels in Prostate Cancer: Immunohistochemical Analysis and Chromogenic In Situ Hybridization
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The androgen receptor (AR) plays a central role in prostate cancer. Evidence from several groups indicates that epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) may enhance AR activity in prostate cancer cell lines. This study was designed to investigate the protein expression of AR, EGFR, and HER2 and to determine whether the EGFR and HER2 genes are amplified in prostate cancer tissues. Materials and Methods The protein expression levels of AR, EGFR, and HER2 in a tissue microarray block of 66 prostate cancer samples were investigated by immunohistochemical analysis and chromogenic in situ hybridization was used to determine whether the EGFR and HER2 genes were amplified in these tissues. Results The AR and EGFR proteins were expressed in 59.1% and 40.9% of prostate cancers, respectively,but their expression levels were not significantly associated with clinicopathologic factors. Of the cases in which tissues were negative for EGFR protein expression, 69.2% were positive for AR protein expression; however, AR protein expression was significantly reduced (44.4%) in tissues in which EGFR protein was expressed. HER2 expression was detected in only 1 case (1.5%). No amplification of the EGFR or HER2 genes was found in prostate cancer specimens. Conclusion This study was limited by small number of subjects, but it can still be inferred that the expression levels of the AR and EGFR proteins are inversely correlated in prostate cancer patients. The potential utility of EGFR and HER2 as prognostic factors or therapeutic targets warrants further study.
Abstract
Purpose The androgen receptor (AR) plays a central role in prostate cancer. Evidence from several groups indicates that epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) may enhance AR activity in prostate cancer cell lines. This study was designed to investigate the protein expression of AR, EGFR, and HER2 and to determine whether the EGFR and HER2 genes are amplified in prostate cancer tissues. Materials and Methods The protein expression levels of AR, EGFR, and HER2 in a tissue microarray block of 66 prostate cancer samples were investigated by immunohistochemical analysis and chromogenic in situ hybridization was used to determine whether the EGFR and HER2 genes were amplified in these tissues. Results The AR and EGFR proteins were expressed in 59.1% and 40.9% of prostate cancers, respectively,but their expression levels were not significantly associated with clinicopathologic factors. Of the cases in which tissues were negative for EGFR protein expression, 69.2% were positive for AR protein expression; however, AR protein expression was significantly reduced (44.4%) in tissues in which EGFR protein was expressed. HER2 expression was detected in only 1 case (1.5%). No amplification of the EGFR or HER2 genes was found in prostate cancer specimens. Conclusion This study was limited by small number of subjects, but it can still be inferred that the expression levels of the AR and EGFR proteins are inversely correlated in prostate cancer patients. The potential utility of EGFR and HER2 as prognostic factors or therapeutic targets warrants further study.
참고문헌 (24)
- 김대석, "The androgen axis in recurrent prostate cancer", CLINICAL CANCER RESEARCH, 10(2), pp.440~448, AMER ASSOC CANCER RESEARCH
- Montgomery RB, "Maintenance of intratumoral androgens in metastatic prostate cancer : a mechanism for castrationresistant tumor growth", Cancer Res, 68, pp.4447~4454 (2008)
- Marks RA, "Epidermal growth factor receptor(EGFR)expression in prostatic adenocarcinoma after hormonal therapy : a fluorescence in situ hybridization and immunohistochemical analysis", Prostate, 68, pp.919~923 (2008)
- Craft N, "A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2", neu tyrosine kinase, 1999, pp.5, 280~285
- Calvo BF, "Human epidermal receptor-2 expression in prostate cancer", Clin Cancer Res, 9, pp.1087~1097 (2003)
- Guo Z, "Regulation of androgen receptor activity by tyrosine phosphorylation", Cancer Cell, 10, pp.309~319 (2006)
- Gregory CW, "Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth", Clin Cancer Res, 11, pp.1704~1712 (2005)
- Mellinghoff IK, "Growth inhibitory effects of the dual ErbB1", ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts, 2002, pp.62, 5254~5259
- Henttu P, "Growth factor regulation of gene expression in the human prostatic carcinoma cell line LNCaP", Cancer Res, 53, pp.1051~1058 (1993)
- Adam RM, "Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function", Endocrinology, 143, pp.4599~4608 (2002)
- Cinar B, "Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycin", Cancer Res, 65, pp.2547~2553 (2005)
- Souder C, "Serum epidermal growth factor receptor", HER-2 predicts poor survival in patients with metastatic breast cancer, 2006, pp.107, 2337~2345
- Signoretti S, "Her-2-neu expression and progression toward androgen independence in human prostate cancer", J Natl Cancer Inst, 92, pp.1918~1925 (2000)
- Oxley JD, "Her-2", neu oncogene amplification in clinically localised prostate cancer, 2002, pp.55, 118~120
- 윤철용, "특집", 전립샘암의 병인, 2010, pp.53(2), 98~106[DOI]
- Steers WD, "5alpha-reductase activity in the prostate", Urology, 58(6 Suppl 1), pp.17~24 (2001)
- Bostwick DG, "Human prostate cancer risk factors", Cancer, 101(10 Suppl), pp.2371~2490 (2004)
- Chen CD, "Molecular determinants of resistance to antiandrogen therapy", Nat Med, 10, pp.33~39 (2004)
- Camp ER, "Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor", Clin Cancer Res, 11, pp.397~405 (2005)
- 이정우, "근치적 전립선적출술 후 생화학적 재발의 예측인자로 Epidermal Growth Factor Receptor의 발현: 전향적 연구", Korean Journal of Urology, 49(11), pp.974~980 (2008), 대한비뇨기과학회
- Cai C, "Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2", Cancer Res, 69, pp.5202~5209 (2009)
- Schlomm T, "Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer", Clin Cancer Res, 13(22 Pt 1), pp.6579~6584 (2007)
- Ross JS, "The Her-2", neu gene and protein in breast cancer 2003 : biomarker and target of therapy, 2003, pp.8, 307~325
- Minner S, "Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer", Clin Cancer Res, 16, pp.1553~1560 (2010)